Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help? - Wikidata - wikimedia - TriplyDB

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

http://www.wikidata.org/entity/Q38009673

about

Graft-versus-host disease affecting oral cavity. A review Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.Complications of allogeneic hematopoietic stem cell transplantation.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia.Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation.Comparison of the Efficacy of Topical Triamcinolone in Orabase and Curcumin in Orabase in Oral Graft-Versus-Host Disease.

P2860

Q27004303-BC1E26D9-F026-40BC-8474-0D9A5FD62508 Q33416874-1A55DE1A-7BA3-441A-9644-35CCAB0E8358 Q38217938-A02F4262-C978-4814-BA71-13AE1CFA0DF2 Q38417073-DB54F599-F6E7-4FA8-8B23-B7FE011FB02E Q45325606-F898FD71-3235-4729-BB87-CB52227A14A7 Q54085734-186DE425-AD10-47EF-84AD-715BB174C56D Q55397395-304157AB-4F3B-40AF-9727-B9928CA0C4B1

P2860

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

http://www.wikidata.org/entity/Q38009673

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

@en

type

label

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

@en

prefLabel

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

@en

P1433

Q38009673-9964C3E0-6A84-4A32-A1C9-40F078016F5B

P1476

Q38009673-BADA7F8A-80F2-40CA-8034-009DA5727E1D

P2093

Q38009673-5C0202E2-42C4-45B9-B515-6CC598667E70

Q38009673-869D1789-38BF-4D0F-9E32-590CD8E29DE0

Q38009673-B11CAF01-AA69-4D8A-BDC8-D383DF1AEBAD

P2860

Q38009673-05A6656F-8F1F-45BD-99B4-770DC97D7818

Q38009673-0847831F-9731-4188-AB9B-A965ED8ED53D

Q38009673-092F848C-34CE-49E9-82EF-9074C9179D77

Q38009673-09342D40-49FD-4D94-AA7D-AC5560CE7AB1

Q38009673-0CCED3FC-4FFE-4D24-B566-DD3B3CB54138

Q38009673-10131B3A-D073-424B-A05C-AA67F257AE52

Q38009673-11DB9174-C81A-4C8B-9C19-66D9DB15B8C2

Q38009673-11F09004-D476-404A-88E8-670449E87DFB

Q38009673-22A85F2E-2515-465D-87CF-B7161CF493D1

Q38009673-35EA143A-4DBA-42B5-AC5F-769EE83D5DAA

P2888

Q38009673-21F807B6-122D-4584-9343-87B2F9161620

P304

Q38009673-8376658C-9701-4555-A953-0949D0C5C0DF

P31

Q38009673-1311004D-88A5-4B7D-AE71-7F441024A7EA

P356

Q38009673-50D8E3A2-6F70-4961-B027-08F3B4B2FF63

P407

Q38009673-25D3E816-FA30-4BB7-A7FD-AC23C7438B81

P433

Q38009673-884A3ADA-97DE-46B1-980B-FAB92469324E

P478

Q38009673-25C54239-20BA-4FA9-AB32-835F900402C3

P577

Q38009673-C5CDF5D2-D33E-49A1-962D-BA528D8C702C

P6179

Q38009673-E8327B8B-F7A2-4463-9D32-0C01E51343C3

P698

Q38009673-9C6F846A-F325-4ACE-85F7-4CBB096CD273

P921

Q38009673-60481A0E-2015-44C5-8A67-B9AA155F2350

P356

P1433

Bone Marrow Transplantation

P1476

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

@en

P2093

R P Gale

http://www.w3.org/2001/XMLSchema#string

S Pavletic

http://www.w3.org/2001/XMLSchema#string

Y P L Linhares

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.

Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature.

Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD

Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

P2888

P304

203-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2012.76

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007173208

http://www.w3.org/2001/XMLSchema#string

P698

22580766

http://www.w3.org/2001/XMLSchema#string

P921